Clinical trial

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

NCT02204345

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention RO5479599 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2014-10-01

PhasePHASE1 / PHASE2

Conditions

Squamous Non-Small Cell Lung Cancerunresolved

Interventions

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

RO5479599DRUG

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

BarcelonaBarcelona, Spain2 TorontoOntario, Canada1 MadridMadrid, Spain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02204345 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.